95. 自己免疫性肝炎 Autoimmune hepatitis Clinical trials / Disease details
臨床試験数 : 52 / 薬物数 : 68 - (DrugBank : 27) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 111
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04371718 (ClinicalTrials.gov) | November 2020 | 29/4/2020 | Effect of JKB-122 on Prednisolone and Azathioprine Induced Remission in Autoimmune Hepatitis (AIH) | A Phase II, Randomized, Double-Blind, Placebo Controlled, Trial of JKB-122 as an Adjunct Therapy to Prednisolone and Azathioprine in the Induction of Remission in Autoimmune Hepatitis (AIH) | Autoimmune Hepatitis | Drug: JKB-122;Other: Placebo | TaiwanJ Pharmaceuticals Co., Ltd | NULL | Not yet recruiting | 18 Years | 65 Years | All | 120 | Phase 2 | NULL |
| 2 | NCT04313205 (ClinicalTrials.gov) | August 2020 | 16/3/2020 | A Pharmacokinetic Study of JKB-122 Tablets Compared to Capsule | A Randomized, Open-label, Multiple-dose, Two-period, Crossover, Study to Investigate the Pharmacokinetic Profile of 2 Formulations of JKB-122 in Healthy Male Subjects | Autoimmune Hepatitis | Drug: JKB-122 in capsule or tablet form | TaiwanJ Pharmaceuticals Co., Ltd | NULL | Not yet recruiting | 20 Years | 45 Years | Male | 8 | Phase 1 | NULL |
| 3 | NCT02556372 (ClinicalTrials.gov) | April 30, 2016 | 20/9/2015 | Liver Test Study of Using JKB-122 in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies | A Phase 2, Pilot Study of JKB-122 to Assess Liver Tests (ALT) in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies | Autoimmune Hepatitis | Drug: JKB-122 | TaiwanJ Pharmaceuticals Co., Ltd | NULL | Completed | 18 Years | N/A | All | 20 | Phase 2 | United States |